BioNTech opens mRNA manufacturing facility at La Trobe

Biopharmaceutical company BioNTech has announced the official opening of its clinical-scale mRNA manufacturing and R&D facility at La Trobe University’s Bundoora campus, located in Melbourne. The inauguration of the facility, which took place last month, marks a major milestone for Victoria’s life sciences sector and sovereign manufacturing capability, as well as for its strategic partnership with BioNTech.

BioNTech’s intention to establish a clinical-scale mRNA manufacturing facility at La Trobe was first announced in December 2023, when the company was contracted by the state government to commission a facility tailored to the needs of the local mRNA ecosystem. Offering state-subsidised access to researchers and biotech startups, the facility aims to enable innovative mRNA-based treatment options to progress efficiently from research to clinical trials — with an initial focus on potential new treatments for cancer, heart disease, neurological and autoinflammatory diseases, as well as potential new vaccines.

The newly inaugurated facility is built around BioNTech’s modular BioNTainer technology, which integrates mRNA drug substance manufacturing, formulation and aseptic filling capabilities within a single site; this set-up provides clinical-scale, end-to-end manufacturing capabilities. BioNTech in Australia is already producing R&D materials for researchers, with the facility expected to become operationally ready for GMP manufacturing by mid to late 2027.

“We have already seen significant demand for R&D and clinical trial material support within the mRNA ecosystem, with potential projects spanning indications including infectious disease, oncology, immunology and neurology with high unmet medical need,” said Dr David Sparling, Site Head at BioNTech Australia. “It is exciting to envision how this facility, once fully operational, can help researchers accelerate their innovations and bring them closer to patients.”

“Our partnership with the Victorian Government demonstrates how public–private collaboration can build lasting capabilities aimed at driving innovation in medicine,” added Dr Sierk Poetting, Chief Operating Officer at BioNTech. “I … look forward to the years ahead as we continue working with our partners to further strengthen the local mRNA ecosystem and empower groundbreaking research and development that are aimed at making a difference for patients worldwide.”

Image credit: La Trobe University.